@article{d623ac7deffa4f7a98aaf44327e06557,
title = "Adjuvant nivolumab after preoperative chemoradiotherapy and surgery in esophageal cancer: A shifting paradigm",
keywords = "adjuvant therapy, esophageal cancer, immune therapy, nivolumab, radiation, surgery, trimodality therapy",
author = "Cameron, {Robert B.} and Ajani, {Jaffer A.} and Wu, {Abraham J.}",
note = "Funding Information: J.A.A. has provided ad hoc paid (received personally) consultations to Bristol Myers Squibb and Merck, and received research funding from these 2 companies (received by UT M. D. Anderson Cancer Center, Houston, Tex). A.J.W. has received research grants from CivaTech Oncology, Inc, consulting fees from MORE Health, and is on the scientific advisory board for Simphotek, Inc (all unrelated to the current manuscript). R.B.C. reported no conflicts of interest. Funding Information: J.A.A. has provided ad hoc paid (received personally) consultations to Bristol Myers Squibb and Merck , and received research funding from these 2 companies (received by UT M. D. Anderson Cancer Center, Houston, Tex). A.J.W. has received research grants from CivaTech Oncology, Inc, consulting fees from MORE Health, and is on the scientific advisory board for Simphotek, Inc (all unrelated to the current manuscript). R.B.C. reported no conflicts of interest. ",
year = "2022",
month = aug,
doi = "10.1016/j.jtcvs.2021.08.082",
language = "English (US)",
volume = "164",
pages = "433--437",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "2",
}